Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lumiracoxib in osteoarthritis of the knee
NCT00267215Phase 3Completed
- Sponsor
- Novartis
- Start
- Nov 2000
- Primary completion
- Feb 2001
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of lumiracoxib in osteoarthritis (OA) (3 arms), sponsored by Novartis. Primary endpoint: Pain Intensity Difference at 3-5 hours. Started Nov 2000; status: completed.
02
Drugs
lumiracoxib
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT00267215.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00267215.